Related Experiment Video
Updated: Apr 2, 2026
05:10
Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection
Published on: August 20, 2007
6.5K
Stem Cell Therapy and Immunological Rejection in Animal Models
Xiaowei Jin, Tongxiang Lin, Yang Xu1
1The Second Clinical Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
Current Molecular Pharmacology
|September 30, 2015
Summary
Human pluripotent stem cells offer regenerative medicine potential. This review explores challenges in immune rejection and cancer risk for stem cell therapies, discussing strategies to improve safety and efficacy.
Area of Science:
- Stem cell biology
- Immunology
- Regenerative medicine
Background:
- Human pluripotent stem cells (hPSCs), including embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), show promise for treating diseases.
- Significant advancements have been made in differentiating hPSCs into various functional cell types.
- Clinical trials are underway for hESC-based therapies, but significant challenges remain.
Purpose of the Study:
- To review the immunogenicity of pluripotent stem cells.
- To discuss strategies for overcoming immune rejection in stem cell therapy.
- To address safety concerns regarding cancer risk and immunogenicity of hiPSC-derived cells.
Main Methods:
- Literature review of recent progress in stem cell immunogenicity.
- Analysis of strategies to mitigate immune rejection.
- Discussion of safety concerns related to induced pluripotent stem cells.
Main Results:
- Allogeneic hESC-derived cells face immune rejection, a major clinical trial bottleneck.
- Patient-specific hiPSCs offer potential for autologous transplantation, reducing immune rejection.
- Concerns persist regarding the oncogenic potential and immunogenicity of hiPSC-derived cells due to reprogramming factors and DNA damage.
Conclusions:
- Overcoming immune rejection is crucial for advancing stem cell therapies.
- Addressing safety concerns of hiPSC-derived cells is essential for clinical translation.
- Developing strategies to enhance the safety and efficacy of pluripotent stem cells is key for regenerative medicine.
